Ltd Nirland Sells 1,368,991 Shares of Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Stock

Conduit Pharmaceuticals Inc. (NASDAQ:CDT) major shareholder Ltd Nirland sold 1,368,991 shares of the business’s stock in a transaction dated Friday, October 4th. The stock was sold at an average price of $0.10, for a total value of $136,899.10. Following the transaction, the insider now owns 7,031,009 shares of the company’s stock, valued at approximately $703,100.90. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Ltd Nirland also recently made the following trade(s):

• On Monday, October 7th, Ltd Nirland sold 939,009 shares of Conduit Pharmaceuticals stock. The shares were sold at an average price of $0.10, for a total value of $93,900.90.
• On Wednesday, October 2nd, Ltd Nirland sold 333,177 shares of Conduit Pharmaceuticals stock. The shares were sold at an average price of $0.10, for a total value of $33,317.70.
• On Monday, September 30th, Ltd Nirland sold 1,016,823 shares of Conduit Pharmaceuticals stock. The stock was sold at an average price of $0.12, for a total value of $122,018.76.

Conduit Pharmaceuticals Stock Performance

Shares of CDT stock opened at $0.11 on Wednesday. Conduit Pharmaceuticals Inc. has a one year low of $0.10 and a one year high of $7.83. The firm’s 50 day moving average price is $0.15 and its 200-day moving average price is $1.51.

Conduit Pharmaceuticals (NASDAQ:CDT) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.07) EPS for the quarter.

Analyst Upgrades and Downgrades

Separately, Berenberg Bank raised shares of Conduit Pharmaceuticals to a “strong-buy” rating in a report on Friday, July 26th.

About Conduit Pharmaceuticals

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.